Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 25
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 1201 | FLAGSHIP PIONEERING INNOVATIONS VII | 12 | 00% | 0 | 12 | 2023–2026 |
| 1202 | FLEXIBLE STEEL LACING | 12 | 00% | 0 | 12 | 2022–2026 |
| 1203 | FOGHORN THERAPEUTICS | 12 | 00% | 2 | 10 | 2022–2024 |
| 1204 | GILGAMESH PHARMACEUTICALS | 12 | 00% | 0 | 12 | 2022–2026 |
| 1205 | GLOCK TECHNOLOGY | 12 | 00% | 0 | 12 | 2022–2024 |
| 1206 | GRAMMER AKTIENGESELLSCHAFT | 12 | 541.7% | 0 | 7 | 2022–2025 |
| 1207 | GUARDIAN GLASS | 12 | 18.3% | 7 | 4 | 2022–2024 |
| 1208 | HUIZHOU DESAY SV AUTOMOTIVE | 12 | 00% | 0 | 12 | 2023–2024 |
| 1209 | ICHOR SYSTEMS | 12 | 00% | 0 | 12 | 2023–2026 |
| 1210 | INTELLIGRATED HEADQUARTERS | 12 | 18.3% | 0 | 11 | 2022–2024 |
| 1211 | JIANGSU HANSOH PHARMACEUTICAL GROUP | 12 | 00% | 0 | 12 | 2022–2026 |
| 1212 | JOY GLOBAL UNDERGROUND MINING | 12 | 00% | 0 | 12 | 2022–2025 |
| 1213 | KANTHAL | 12 | 18.3% | 0 | 11 | 2018–2025 |
| 1214 | KIEKERT | 12 | 00% | 0 | 12 | 2024–2026 |
| 1215 | KING STEEL MACHINERY | 12 | 00% | 0 | 12 | 2023–2025 |
| 1216 | KOKUSAI KEISOKUKI | 12 | 00% | 0 | 12 | 2022–2026 |
| 1217 | KUMQUAT BIOSCIENCES | 12 | 00% | 0 | 12 | 2024–2026 |
| 1218 | LARGAN DIGITAL | 12 | 00% | 0 | 12 | 2022–2025 |
| 1219 | LARGAN INDUSTRIAL OPTICS | 12 | 18.3% | 0 | 11 | 2023–2025 |
| 1220 | LENZING AKTIENGESELLSCHAFT | 12 | 325% | 2 | 7 | 2021–2024 |
| 1221 | LIFTRA IP APS | 12 | 18.3% | 0 | 11 | 2022–2025 |
| 1222 | LILIUM | 12 | 00% | 3 | 9 | 2023–2026 |
| 1223 | MIDREX TECHNOLOGIES | 12 | 216.7% | 0 | 10 | 2022–2024 |
| 1224 | MODERNATX | 12 | 00% | 7 | 5 | 2022–2026 |
| 1225 | NCIPHER SECURITY | 12 | 00% | 0 | 12 | 2022–2025 |
| 1226 | NEOPERL | 12 | 00% | 2 | 10 | 2022–2026 |
| 1227 | NEUROCRINE BIOSCIENCES | 12 | 00% | 1 | 11 | 2022–2026 |
| 1228 | NOVAVAX | 12 | 00% | 0 | 12 | 2022–2025 |
| 1229 | OILES | 12 | 18.3% | 0 | 11 | 2022–2024 |
| 1230 | OMICRON ELECTRONICS | 12 | 325% | 0 | 9 | 2022–2025 |
| 1231 | OPEX | 12 | 18.3% | 0 | 11 | 2022–2026 |
| 1232 | ORION | 12 | 216.7% | 0 | 10 | 2022–2026 |
| 1233 | PERFETTI VAN MELLE | 12 | 18.3% | 0 | 11 | 2022–2026 |
| 1234 | PIOLAX | 12 | 00% | 0 | 12 | 2022–2026 |
| 1235 | PLANSEE SE | 12 | 00% | 0 | 12 | 2022–2025 |
| 1236 | POWERCELL SWEDEN | 12 | 216.7% | 0 | 10 | 2022–2025 |
| 1237 | PRECIGEN | 12 | 00% | 1 | 11 | 2022–2026 |
| 1238 | PTC THERAPEUTICS | 12 | 00% | 2 | 10 | 2022–2026 |
| 1239 | RIGEL PHARMACEUTICALS | 12 | 325% | 1 | 8 | 2022–2026 |
| 1240 | RUBRIK | 12 | 00% | 1 | 11 | 2022–2023 |
| 1241 | SAATI | 12 | 216.7% | 0 | 10 | 2022–2025 |
| 1242 | SAINT GOBAIN SEKURIT FRANCE | 12 | 18.3% | 0 | 11 | 2021–2026 |
| 1243 | SANA BIOTECHNOLOGY | 12 | 00% | 3 | 9 | 2022–2026 |
| 1244 | SANTONI | 12 | 18.3% | 0 | 11 | 2021–2025 |
| 1245 | SAREPTA THERAPEUTICS | 12 | 18.3% | 1 | 10 | 2022–2025 |
| 1246 | SD BIOSENSOR | 12 | 00% | 1 | 11 | 2023–2026 |
| 1247 | SHANGHAI HANSOH BIOMEDICAL | 12 | 00% | 0 | 12 | 2022–2026 |
| 1248 | SHANGHAI JEMINCARE PHARMACEUTICAL | 12 | 18.3% | 4 | 7 | 2023–2024 |
| 1249 | SHANGHAI ROYE ELECTRIC | 12 | 1083.3% | 0 | 2 | 2022–2025 |
| 1250 | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL | 12 | 00% | 0 | 12 | 2022–2026 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →